Compare ResMed Inc. (RMD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Recursion Pharmaceuticals Inc — how do they compare? ResMed Inc. trades at $196 (market cap $28.81B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: ResMed Inc. is far larger — about 18.8× Recursion Pharmaceuticals Inc's market cap, and ResMed Inc. pays a 1.21% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RMD | RXRX | |
|---|---|---|
Market Cap | $28.81B | $1.53B |
Sector | Health | Health |
52-Week High | $293.73 | $6.79 |
52-Week Low | $182.82 | $2.84 |
Enterprise Value | $27.99B | $946.50M |
Dividend Yield | 1.21% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
